Recent Quotes (30 days)

You have no recent quotes
chg | %

Cipher Pharmaceuticals Inc  

(Public, TSE:CPH)   Watch this stock  
Find more results for TSE:DND
+0.65 (4.55%)
Mar 2 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 13.65 - 15.00
52 week 7.11 - 19.52
Open 14.28
Vol / Avg. 160,775.00/38,002.00
Mkt cap 386.81M
P/E 12.06
Div/yield     -
EPS 1.24
Shares 25.89M
Beta -0.69
Inst. own     -
Mar 3, 2015
Cipher Pharmaceuticals Inc at Cowen Health Care Conference - 8:40AM EST - Add to calendar
Feb 25, 2015
Q4 2014 Cipher Pharmaceuticals Inc Earnings Release
Feb 25, 2015
Q4 2014 Cipher Pharmaceuticals Inc Earnings Call - Webcast

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 120.04% 92.43%
Operating margin 62.40% 67.22%
EBITD margin - 71.39%
Return on average assets 53.43% 64.43%
Return on average equity 64.75% 97.60%
Employees 13 -
CDP Score - -


5650 Tomken Road, Unit 16
+1-905-6025840 (Phone)
+1-905-6020628 (Fax)

Website links


Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company focused on dermatology. The Company develops improved formulations of known molecules using drug delivery technologies. The Company is engaged in clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. The Company has three commercial products and a fourth in development. Its products include Absorica/Epuris, which has isotretinoin as active ingredient; Lipofen, which has fenofibrate as active ingredient, and ConZi/Durela, which has tramadol as active ingredient. The Company is focused on growth through new products and additional out-licensing agreements. The Company also owns seven pre-clinical compounds, including Nanolipolee-007, a liposomal formulation of a plant-derived compound that is a cholesterol-transport inhibitor for the treatment of melanoma and other cancers.

Officers and directors

Gerald P. McDole Independent Chairman of the Board
Age: 74
Shawn Patrick O'Brien President, Chief Executive Officer
Norman C. Evans Chief Financial Officer, Secretary
Joan Chypyha Vice President - Marketing and Sales
Linda Melanie Angaritis Vice President - Global Regulatory Compliance and Quality
Lynne Bulger Vice President - Medical and Clinical Affairs
Peter Weiler Vice President - Business Development
Stefan Aigner M.D. Independent Director
William D. Claypool M.D. Independent Director
Age: 61
John D. Mull M.D. Independent Director